4results about How to "Reduce infarct size" patented technology

The invention relates to application of tsRNA-3025a as a prognostic marker of acute myocardial infarction and a treatment target spot of myocardial ischemia reperfusion injury. A DNA (Deoxyribonucleic Acid) sequence corresponding to the tsRNA-3025a is shown as SEQ ID NO: 1: 5 '-ATCCTGCCGACTACGCCA-3'. The tsRNA-3025a can be used for treating acute myocardial infarction and myocardial ischemia reperfusion injury. In the aspect of prognosis, a detection kit is provided, and the risk of heart failure and short-term adverse events of a patient is evaluated by quantitatively detecting the expression level of the tsRNA. In the aspect of treatment, the invention provides the application of the anti-tagomir for inhibiting the function or expression of tsRNA-3025a in the preparation of the medicine for treating the myocardial ischemia reperfusion injury, and the anti-tagomir is subjected to specific chemical modification. A novel biomarker is provided for prognosis risk stratification of acute myocardial infarction, and an effective treatment strategy is provided for prevention and treatment of myocardial ischemia-reperfusion injury.

The application discloses a multifunctional injectable hydrogel and a preparation method and application thereof, and relates to the technical field of multifunctional hydrogel preparation and application. In the preparation, CMC-AGE and OD-SH are prepared respectively, and DSPE-se-se-PEG@AC NPs nanoparticles are prepared, then the multifunctional injectable hydrogel is prepared by forming a hydrogel through CMC-AGE and OD-SH and adding DSPE-se-se-PEG@AC NPs nanoparticles and / or beta nerve growth factor. The application also includes the multifunctional injectable hydrogel prepared by the above method and the application thereof. The application constructs an in-situ hydrogel delivery platform with good biocompatibility, is used for co-delivery of DSPE-se-se-PEG@AC NPs and NGF, is used in ischemic stroke treatment, and reshapes the pathological microenvironment of a cerebral infarction area, so that cerebral ischemic injury is reduced.

The application relates to application of miRNA and / or a miRNA agonist in preparation of a medicine for preventing and / or treating myocardial ischemia-reperfusion injury, and belongs to the technical field of biological medicine. The medicine is administered through skeletal muscle injection, is secreted to a circulation system after expression on the skeletal muscle, is delivered to heart tissue by taking extracellular vesicles as carriers, and thus regulates myocardial cell functions. According to the animal model verification result, the miRNA can be delivered to the heart by the extracellular vesicles secreted by the skeletal muscle through injection of the medicine into the skeletal muscle, the expression level of the miRNA in the I / RI heart is significantly increased, the myocardial infarction area is effectively reduced, myocardial cell apoptosis is inhibited, myocardial fibrosis is reduced, and heart function is improved, a brand-new intervention strategy is provided for treatment of myocardial ischemia-reperfusion injury and related heart diseases, and a brand-new idea is opened up for research and development of heart failure treatment medicines.

The invention belongs to the technical field of biology, and particularly relates to a mesenchymal stem cell exosome for overexpressing miR-29 and application of the mesenchymal stem cell exosome. The miR-29 is overexpressed by the mesenchymal stem cells, so that the content of key miRNA in the exosome is remarkably increased, and the function of the exosome in cerebral ischemia treatment is enhanced; the exosome is used as a cell-free treatment mode, so that the risks of cell proliferation, differentiation, immunological rejection and the like possibly caused by MSC transplantation are avoided, and standardization and large-scale preparation are easier; the mesenchymal stem cell exosome of the overexpressed miR-29 can simultaneously realize multiple effects, such as protecting neurons, promoting vascular regeneration, inhibiting inflammatory response, repairing blood-brain barrier and the like, so that cerebral arterial thrombosis can be more comprehensively treated; according to the scheme, through miRNA function enhancement, a stronger treatment effect is provided, and the problems of insufficient function, low miRNA content and weak targeting in existing mesenchymal stem cell exosome treatment are solved.